Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Dx Firm Atlas Genetics Lands $4.1M in VC Funds

NEW YORK (GenomeWeb News) – Atlas Genetics has gained £2.1 million ($4.1 million) in venture capital from previous and new investors, which it will use to conduct clinical evaluations for a clinical diagnostic test for Group B Streptococcus in pregnant women.
 
Investors in this round of financing included South West Ventures Fund, GEIF, and private investors through the SWAIN business angel’s network. New investors included Finance South West Growth Fund and Braveheart Ventures.
 
Atlas, a spin-out from Bath University in the UK, is developing a point-of-care portable system to deliver molecular diagnostic results in 30 minutes. The firm is working on tests for meningitis, Chlamydia, Group B Streptococcus and for methicillin-resistant Staphylococcus aureus.
 

The Scan

For STEM Students to Stay

New policy changes will make it easier for international STEM students to stay in the US after graduation, the Wall Street Journal reports.

To Inform or Not, To Know or Not

The New York Times writes that some genetic biobanks may re-contact donors if they spot something troublesome, but it notes that not all donors want that information.

Rapid Test Studies

Researchers are examining why rapid tests may be less effective at detecting the Omicron variant and how to improve them, NPR says.

PLOS Papers on SARS-CoV-2 Diversity in Delaware, Metastatic Breast Cancer, Adiposity GWAS

In PLOS this week: genomic analysis of SARS-CoV-2 isolates from Delaware, gene expression and protein-protein interaction patterns in metastatic breast cancer, and more.